mRNA Shot Offers Efficacy for Influenza-Like Illness
A new investigational mRNA-based vaccine, mRNA-1010, has demonstrated superior efficacy compared to a standard-dose seasonal influenza vaccine in preventing influenza-like illness in adults aged 50 and older. The phase 3 trial showed a relative vaccine efficacy of 26.6% for mRNA-1010, with a comparable safety profile. However, adverse events were reported more frequently with mRNA-1010, including injection-site pain and fatigue.
- ▪The mRNA-1010 vaccine showed a relative vaccine efficacy of 26.6% compared to the standard-dose vaccine.
- ▪Adverse events were more common with mRNA-1010, particularly injection-site pain and fatigue.
- ▪The study involved 40,703 participants aged 50 years or older during the 2024-2025 influenza season.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/mrna-vaccine-shows-superior-efficacy-influenza-illness-older-2026a1000hhe?src=rss |
| Publication time | Wed, 27 May 2026 08:01:18 EDT |
| Retrieval time | 2026-05-27T12:07:59.258Z |
| Last seen | 2026-05-27T12:07:59.258Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | HijEp9WpLBuM |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:A single dose of an investigational mRNA-based vaccine called mRNA-1010 vaccine showed superior efficacy to a licensed standard-dose inactivated seasonal influenza vaccine in preventing influenza-like illness among adults aged 50 years or older, with a comparable safety profile. METHODOLOGY:This phase 3 randomized trial, conducted during the 2024-2025 Northern Hemisphere influenza season, investigated the efficacy of the mRNA-1010 vaccine — which encodes hemagglutinin glycoproteins from World Health Organization-recommended influenza strains — vs licensed standard‑dose seasonal influenza vaccines for preventing laboratory‑confirmed influenza‑like illness in adults aged 50 years or older.Overall, 40,703 vaccine recipients were assigned to receive a single intramuscular dose of…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
